Martin Shkreli NLJ/Diego M. Radzinschi

The securities fraud trial for pharmaceutical executive Martin Shkreli, now in its fifth week, is grinding to its conclusion.

On Monday, prosecutors from the Eastern District U.S. Attorney’s Office called their final witness, FBI agent Michael Braconi, and said they could rest as early as Tuesday.

Shkreli, who achieved notoriety when he increased the price of a life-saving drug for HIV and AIDS sufferers from $13.50 to $700 per pill, is accused of defrauding investors in two hedge funds he founded and paying them back by misappropriating $11 million in assets from Retrophin, another firm also co-founded by Shkreli.

Assistant U.S. attorneys Alixandra Smith, Girish Srinivasan and Jacquelyn Kasulis are prosecuting the case.

Shkreli has kept the trial interesting with occasional out-of-courtroom antics, like the time he visited an overflow courtroom being used by reporters covering the case and held an impromptu press conference.

Benjamin Brafman, Shkreli’s lead counsel, told Eastern District Judge Kiyo Matsumoto on Monday that his client does not plan to testify.

Shkreli’s legal team also includes Marc Agnifilo, Jacob Kaplan and Andrea Zellan of Brafman & Associates.